05-Nov-2026 13:25:59
SHILPA MEDICARE Q2 FY27: 20+ NEW APIs UNDER DEVELOPMENT, SIX LATE-STAGE CDMO PROGRAMS, EU SUPPLIES TO BEGIN H2 FY27; BIOSIMILAR PIPELINE & CAPACITY UTILISATION TO DRIVE MARGIN EXPANSION
• FDF Pipeline: Nilotinib, Axitinib and Rotigotine in hybrid portfolio; complex generics include Abraxane, Xtandi and Abiraterone. • Novel Drug Development: Progressing NoRUDCA for NAFLD and OERIS, a long-acting Ondansetron ER injectable. • CDMO Expansion: Six late-stage programmes, including four under registration; EU commercial supplies expected to begin in H2 FY27. • New Drug Development: Two New Biological Entity (NBE) programmes expected to enter human studies in H2 FY27. • API Pipeline: Over 20 new APIs under development, with complex API launches, specialty products and capacity expansion supporting growth. • Biologics: Strong biosimilar pipeline, with several major assets completing clinical trials, expected to support future revenue growth. • Recombinant Albumin: Phase III trials in India and Europe planned for H2 FY27; Orion partnership supports therapeutic applications. • Licensing Income: Multiple licensed assets progressing towards long-term commercial supply agreements. • Operating Leverage: Underutilised capacity across Biosimilars, CDMO and NDDS offers significant operating leverage potential. • Margin Outlook: Management expects improved capacity utilisation to accelerate revenue growth and deliver meaningful EBITDA margin expansion.
SHILPA MEDICARE LTD